Clinical Study Of Antipyretic Granule Treatment Of Exogenous Febrile Upper Respiratory Tract Infection

Objective:To investigate the clinical efficacy and the safety of antipyretic granule in treating the patients with viral upper respiratory tract infection.Methods:A total of102patients with viral upper respiratory tract infection recruited from Jangsu Provincial Hospital and Kunshan City Hospital of Traditional Chinese Medicine (from September to December in2010) were randomly divided into three groups (1:1:1ratio) in a double-blind fashion. The treatment group (treated with antipyretic granule,34cases), the control group (treated with bufferin cold,34cases) and the low dose febrifuge granule control group were34cases. The course of treatment was3days in these groups. The changes of body temperature and the clinical symptoms were observed and analyzed before and after treatment including①Antipyretic effect (the range of the reduction of patients’temperature were measured1,2,3,4hours after medication),②Fever clearance times (the time from the start of antipyretic therapy to the time that the temperature fell below and remained less or equal37.2℃),③Clinical relevance (effectiveness of relief of clinical symptoms).④Clinical cure rate.Result:(1) Antipyretic effects:Fever subsided markedly in the treatment group (treated with febrifuge granule)within4hours after medication (P<0.05), The bufferin cold control group had fever subsided within4hours (P<0.05), but there were no significant statistical difference between the treatment group and control group (P>0.05). There were significant difference between the placebo control group and the febrifuge granule group and bufferin cold control group within4hours (P<0.05). It indicated that both the febrifuge granule group and the bufferin cold control group had significant antipyretic effect without difference, and the placebo group had no therapeutic effect.(2) Fever clearance time:Of these patients in the febrifuge granule group, the average fever clearance time was23.11hours. The incidence of bufferin cold control group was better than the placebo control group (P<0.05), There was no significant difference between the febrifuge granule group and the bufferin cold control group (P>0.05).According to statistical results; there was significant effect in the combination therapy with placebo group. However, febrifuge granule group did not find the effect in combined therapy, which indicated that the efficacy of the febrifuge granule group was better than the placebo group.(3) Clinical relevance:The total effective rate of treatment group (febrifuge granule group) was more than90%, which was significantly higher than bufferin cold control group and the placebo control group on decreasing body temperature, ameliorating clinical symptoms such as mild fever、high fever、shivering、chills、sweating、nasal stiffness、rhinorrhea、sneezing、sore throat、poor appetite、nausea、vomiting、diarrhea、and constipation etc.(4) Clinical cure rate:The effective rate of febrifuge granule group was around84.71%, which was significantly higher than those of bufferin cold control group(70.11%) and the placebo control group(51.72%)(P<0.05)。Conclusion:Antipyretic granule could be used as an effective method in the treatment of viral upper respiratory tract infection fever.